Marcin Frąckiewicz

February 3, 2026, 9:30 PM EST. Omnicell (OMCL) shares recently hovered near $46 after a week of 7.8% decline and a slight 2% gain over the past month, reflecting mixed investor sentiment. Despite falling 21% and 65.2% below its 3- and 5-year peaks respectively, the company's healthcare technology position keeps it in focus. A Discounted Cash Flow (DCF) model indicates the stock is about 11.2% undervalued, with an intrinsic value estimate of $51.87 versus the current price, driven by projected free cash flow growth to $105.6 million by 2030. However, valuation scores are modest at 2 out of 6, and Omnicell's high Price-to-Earnings ratio of approximately 103.7 signals elevated expectations amid market reassessment of risks and growth prospects.